ATE82506T1 - Stabilisierung von wachstumshormonen. - Google Patents

Stabilisierung von wachstumshormonen.

Info

Publication number
ATE82506T1
ATE82506T1 AT87307406T AT87307406T ATE82506T1 AT E82506 T1 ATE82506 T1 AT E82506T1 AT 87307406 T AT87307406 T AT 87307406T AT 87307406 T AT87307406 T AT 87307406T AT E82506 T1 ATE82506 T1 AT E82506T1
Authority
AT
Austria
Prior art keywords
stabilization
growth hormone
amino acids
growth
stabilizers
Prior art date
Application number
AT87307406T
Other languages
English (en)
Inventor
Edwin J Hamilton Jr
Bruce D Burleigh
Original Assignee
Imcera Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8198005&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE82506(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imcera Group Inc filed Critical Imcera Group Inc
Application granted granted Critical
Publication of ATE82506T1 publication Critical patent/ATE82506T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Liquid Deposition Of Substances Of Which Semiconductor Devices Are Composed (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Chemical Vapour Deposition (AREA)
AT87307406T 1987-08-21 1987-08-21 Stabilisierung von wachstumshormonen. ATE82506T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP87307406A EP0303746B2 (de) 1987-08-21 1987-08-21 Stabilisierung von Wachstumshormonen

Publications (1)

Publication Number Publication Date
ATE82506T1 true ATE82506T1 (de) 1992-12-15

Family

ID=8198005

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87307406T ATE82506T1 (de) 1987-08-21 1987-08-21 Stabilisierung von wachstumshormonen.

Country Status (5)

Country Link
EP (1) EP0303746B2 (de)
AT (1) ATE82506T1 (de)
DE (1) DE3782737T3 (de)
ES (1) ES2044941T5 (de)
HU (1) HU202117B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5122512A (en) * 1988-09-12 1992-06-16 Pitman-Moore, Inc. Swine growth promoting composition
US5384132A (en) * 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
SE9002731D0 (sv) * 1990-08-24 1990-08-24 Kabivitrum Ab Product comprising growth factor
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
WO1993019773A1 (en) * 1992-04-07 1993-10-14 Pitman-Moore, Inc. Lyophilized somatotropin formulations
ES2286868T3 (es) * 1992-07-31 2007-12-01 Genentech, Inc. Composicion acuosa a base de hormana del crecimiento humana.
NZ257212A (en) 1992-09-29 1996-11-26 Inhale Therapeutic Syst Parathyroid hormone formulations comprising a biologically active n-terminal fragment of the hormone
NZ262634A (en) * 1993-02-23 1997-02-24 Genentech Inc Stabilizing polypeptides against degradation by organic solvents by admixing the peptide with trehalose or mannitol
US5652216A (en) * 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
DE69420872T2 (de) * 1994-06-17 2000-01-13 Applied Research Systems Ars Holding N.V., Curacao Hgh enthaltende pharmazeutische zubereitungen
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
IL115592A (en) * 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
AUPN801296A0 (en) 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
ZA9711731B (en) 1996-12-31 1998-07-01 Monsanto Co Aqueous glycerol formulations of somatotropin
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
HU0800692D0 (en) * 1999-10-04 2009-01-28 Novartis Vaccines & Diagnostic Stabilized liquid polypeptide-containing pharmaceutical compositions
AU2001238540A1 (en) 2000-02-24 2001-09-03 Monsanto Technology Llc Non-aqueous injectable formulations for extended release of somatotropin
MXPA03000073A (es) * 2000-06-26 2003-09-25 Monsanto Technology Llc Formulaciones que contienen agente tensioactivo no acuoso para la liberacion prolongada de somatrotopina.
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
JP2004515467A (ja) 2000-08-07 2004-05-27 ネクター セラピューティックス 吸入可能な、噴霧乾燥した、最少の凝集物を有する４−ヘリックスバンドルタンパク質粉末
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6875432B2 (en) 2000-10-12 2005-04-05 Genentech, Inc. Reduced-viscosity concentrated protein formulations
JP4686361B2 (ja) 2002-12-31 2011-05-25 アルタス ファーマシューティカルズ インコーポレイテッド ヒト成長ホルモンの結晶およびその調製方法
US20040224886A1 (en) 2003-01-08 2004-11-11 Chiron Corporation Stabilized compositions comprising tissue factor pathway inhibitor protein or tissue factor pathway inhibitor variant proteins
ZA200507757B (en) 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
US8409586B2 (en) 2006-07-06 2013-04-02 Daewoong Co., Ltd. Stable liquid formulation of human growth hormone
RU2011140498A (ru) 2009-03-06 2013-04-20 Дженентек, Инк. Препарат антител
SMT201700454T1 (it) 2010-03-01 2018-01-11 Bayer Healthcare Llc Anticorpi monoclonali ottimizzati contro inibitore della via di fattore tissutale (tfpi)
JP6023696B2 (ja) * 2010-03-31 2016-11-09 スタビリテック リミテッド ミョウバンアジュバントおよびミョウバンアジュバント化ワクチンの保存方法
US20130089912A1 (en) * 2011-10-06 2013-04-11 Gloria Elliott Methods and compositions for the stabilization of biologic material
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
JP5487276B2 (ja) * 2012-11-12 2014-05-07 デウン カンパニー，リミテッド ヒト成長ホルモンを含有する安定した液状製剤
DE102020125874A1 (de) * 2020-10-02 2022-04-07 Dr. Kurt Wolff Gmbh & Co. Kg Zusammensetzung zur Behandlung von Haaren und der Haut

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0193917A3 (de) * 1985-03-06 1987-09-23 American Cyanamid Company Wasserdispersible und wasserlösliche Polymerzusammensetzungen für parenterale Anwendung
US4670249A (en) * 1985-04-12 1987-06-02 International Minerals & Chemical Corp. Growth-promoting compositions

Also Published As

Publication number Publication date
HU202117B (en) 1991-02-28
EP0303746B2 (de) 1998-12-02
ES2044941T3 (es) 1994-01-16
EP0303746A1 (de) 1989-02-22
EP0303746B1 (de) 1992-11-19
ES2044941T5 (es) 1999-02-16
DE3782737D1 (de) 1992-12-24
HUT44706A (en) 1988-04-28
ES2044941T4 (es) 1996-07-16
DE3782737T2 (de) 1993-04-01
DE3782737T3 (de) 1999-05-20

Similar Documents

Publication Publication Date Title
ATE82506T1 (de) Stabilisierung von wachstumshormonen.
ATE248922T1 (de) Hormonanaloge mit mehreren ctp-erweiterungen
HU896498D0 (en) Process for preparation of low volatility salts
AU6020186A (en) Process for production of dry bioactive recombinant growth hormones
SE8505048D0 (sv) Nutritionsemulsion med syretransporterande egenskaper
ATE65366T1 (de) Produktion von eiern.
EP0203649A3 (en) Pharmaceutic composition based on diphoshonates for the treatment of the arthrosis
DE3867445D1 (de) Injizierbare loesung des thioctsaeuresalzes mit trometamol und/oder basischen aminosaeuren.
DE3587230D1 (de) Enzymatisches verfahren.
ATE114470T1 (de) Behandlung von intraocularem druck mit einer synergistischen kombination zur ophthalmischen verwendung.
DE3777367D1 (de) Hirudin-variante, deren verwendung und herstellung.
EP0303251A3 (en) Modified tpa-containing injection composition
FI95777C (fi) Menetelmä 8-N-(dietyyliaminoetyyli)rebekkamysiinin stabiilin vesiliuoksen valmistamiseksi
AU3232784A (en) Compositions containing s-adenosyl-l methionine
NZ235297A (en) Aqueous solution containing a protein and anionic polymer or salt and method of increasing the protein concentration of an aqueous solution
DE59100098D1 (de) Parenteral applizierbares lagerbestaendiges immunstimulierendes praeparat, verfahren zu seiner herstellung und dessen verwendung.
EP0142597A3 (en) Curative composition for buerger's disease
DK15088A (da) Antibakterielt lyofiliseret praeparat
ATE53491T1 (de) Niedrig osmotisches hypokalorisches waessriges praeparat fuer die infusion.
DE3167839D1 (en) Method for preparing n-(4-(((2,4-diamino-6-pteridinyl)-methyl)methylamino)benzoyl)glutamic acid
ES8706838A1 (es) Metodo para conservar cueros, pellejos y pieles crudos de animales
EP0260092A3 (en) Optically active beta-amino acid derivatives and their salts, and processes for producing the same
DK0432092T3 (da) Pesticidsammensætning
BG50927A3 (bg) Метод за получаване на стабилизирани стимулиращи растежа хормони

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee